PT - JOURNAL ARTICLE AU - Daniel Ayoubkhani AU - Kamlesh Khunti AU - Vahé Nafilyan AU - Thomas Maddox AU - Ben Humberstone AU - Sir Ian Diamond AU - Amitava Banerjee TI - Epidemiology of post-COVID syndrome following hospitalisation with coronavirus: a retrospective cohort study AID - 10.1101/2021.01.15.21249885 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.15.21249885 4099 - http://medrxiv.org/content/early/2021/01/15/2021.01.15.21249885.short 4100 - http://medrxiv.org/content/early/2021/01/15/2021.01.15.21249885.full AB - Objectives The epidemiology of post-COVID syndrome (PCS) is currently undefined. We quantified rates of organ-specific impairment following recovery from COVID-19 hospitalisation compared with those in a matched control group, and how the rate ratio (RR) varies by age, sex, and ethnicity.Design Observational, retrospective, matched cohort study.Setting NHS hospitals in England.Participants 47,780 individuals (mean age 65 years, 55% male) in hospital with COVID-19 and discharged alive by 31 August 2020, matched to controls on demographic and clinical characteristics.Outcome measures Rates of hospital readmission, all-cause mortality, and diagnoses of respiratory, cardiovascular, metabolic, kidney and liver diseases until 30 September 2020.Results Mean follow-up time was 140 days for COVID-19 cases and 153 days for controls. 766 (95% confidence interval: 753 to 779) readmissions and 320 (312 to 328) deaths per 1,000 person-years were observed in COVID-19 cases, 3.5 (3.4 to 3.6) and 7.7 (7.2 to 8.3) times greater, respectively, than in controls. Rates of respiratory, diabetes and cardiovascular events were also significantly elevated in COVID-19 cases, at 770 (758 to 783), 127 (122 to 132) and 126 (121 to 131) events per 1,000 person-years, respectively. RRs were greater for individuals aged <70 than ≥ 70 years, and in ethnic minority groups than the White population, with the biggest differences observed for respiratory disease: 10.5 [9.7 to 11.4] for <70 years versus 4.6 [4.3 to 4.8] for ≥ 70 years, and 11.4 (9.8 to 13.3) for Non-White versus 5.2 (5.0 to 5.5) for White.Conclusions Individuals discharged from hospital following COVID-19 face elevated rates of multi-organ dysfunction compared with background levels, and the increase in risk is neither confined to the elderly nor uniform across ethnicities. The diagnosis, treatment and prevention of PCS require integrated rather than organ- or disease-specific approaches. Urgent research is required to establish risk factors for PCS.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; KK is Chair of the Ethnicity Subgroup of the Independent Scientific Advisory Group for Emergencies (SAGE), a member of Independent SAGE, a Trustee of the South Asian Health Foundation (SAHF), and Director of the University of Leicester Centre for Black Minority Ethnic Health; and AB is a Trustee of the SAHF, and has received a research grant unrelated to the current work from AstraZeneca.Funding StatementThere was no external funding for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the National Statistician's Data Ethics Advisory Committee [NSDEC(20)12].All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIn accordance with NHS Digital's Information Governance (IG) requirements, it is not possible for the study data to be shared.